[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Leipzig University Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100588347","delayed-against-rapid-sequence-induction-in-adults-with-medical-diseases-undergoing-emergency-endotracheal-intubation-100588347",false,"NCT06940219","Delayed Against Rapid Sequence Induction in Adults With Medical Diseases Undergoing Emergency Endotracheal Intubation.","Delayed Against Rapid Sequence Induction in Critically Ill Adults With Medical Diseases Undergoing Emergency Endotracheal Intubation: The DARSITUBE-study, a Monocentric Randomized Controlled Trial","DARSITUBE","Inclusion Criteria:\n\n* Adult patients 18 years or older in need of emergency endotracheal intubation in the following 60 minutes.\n* The planned operateur routinely performs endotracheal intubation in critically ill patients.\n\nExclusion Criteria:\n\n* Endotracheal Intubation performed during cardiopulmonary resuscitation or during \"unstable ROSC\", defined as Norepinephrine or Epinephrine dose \\> 0,5 µg\u002FkgKG\u002Fmin after return of spontaneous circulation.\n* Participation in the study is not warranted because of increased risk for the patient or otherwise not justifiable (e.g. active oral bleeding).\n* Known allergy against Ketamine, Esketamine, Midazolam or Rocuronium.\n* Known contraindication against Ketamine, Esketamine Midazolam or Rocuronium.\n* Known or anticipated difficult airway with indication for awake fiberoptic intubation.\n* Women with known pregnancy or breastfeeding.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if it is feaseble to conduct a superiority trial comparing two methods for endotracheal intubation in critically ill patients. It will also learn about validity of outcomes regarding endotracheal intubation. The main questions it aims to answer are:\n\n* Does performing intubation via Delayed Sequence Induction lower the incidence of severe hemodynamic complications compared to Rapid Sequence Induction?\n* How are hemodynamic complications in the severely ill to be measured in order to minimize bias?\n\nParticipants will:\n\n* receive emergency endotracheal intubation via Delayed or Rapid Sequence induction\n* receive a phone call 90 days after endotracheal intubation\n* outcome parameters outside of follow up phone calls will be routinely collected during the regular ICU-stay, there won't be any additional testing",[27],"Intubation in Intensive Care Units",[29,30,31,32,33,34,35],"Intubation","Airway Management","Acute respiratory failure","Intensive Care Unit","Rapid Sequence Induction","Delayed Sequence Induction","Intubation in intensive care units","RECRUITING","2025-07-01",{"date":39,"type":40},"2025-07-04","ACTUAL",{"date":42,"type":40},"2025-06-27",{"date":44,"type":21},"2027-11",{"name":46,"class":47},"Leipzig University Medical Center","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":48},"100414371","quality-of-life-in-women-with-x-linked-adrenoleukodystrophy-100414371","NCT04675749","Quality of Life in Women with X-linked Adrenoleukodystrophy","Quality of Life in Female Carriers of X-linked Adrenoleukodystrophy","X-ALD_QoL","Inclusion Criteria:\n\n* Informed consent obtained from the participant\n* Females ≥18 years at the time of consent, with proven X-ALD as defined by\n\n  1. Elevated VLCFA values, or\n  2. Mutation in ABCD1 gene\n\nExclusion Criteria:\n\n* No informed consent and assent\n* Current pregnancy","FEMALE",{"count":20,"type":21},"OBSERVATIONAL","X-linked adrenoleukodystrophy (X-ALD) is a hereditary white matter disorder caused by mutations in the ABCD1 gene leading to disturbances in the metabolism of fatty acids. This results in an accumulation of very long chain fatty acids (VLCFA) in the cells of the body causing damage to the central nervous system (white matter of the brain and spinal cord). The most common adult-onset X-ALD phenotype is adrenomyeloneuropathy (AMN), a slowly progressive myelopathic variant with demyelination of the long tracts in the spinal cord, clinically manifested as slowly progressive spastic paraparesis, sensory ataxia, bladder and sexual dysfunction.\n\nAlthough this rare disease is inherited X-linked, previous research revealed that up to 80% of heterozygous women develop AMN symptoms during their lifetime.\n\nThe primary objectives of this study are 1) to assess the prevalence of symptomatic courses in female carriers of X-ALD and 2) to determine the impact of AMN symptoms on the quality of life of affected women in various areas (including everyday life, work, social network, sleep quality, sexuality, mood).\n\nParticipants are asked to fill in self-report questionnaires, which are available in English, German, French, Spanish, and Italian, and are provided electronically on the online platform Leuconnect (https:\u002F\u002Fwww.leuconnect.com) launched by European Leukodystrophies Association (ELA) international (https:\u002F\u002Felainternational.eu\u002F).",[62],"X-linked Adrenoleukodystrophy",[64,65,66,67,68,69,70,71,72,73,74,75,76],"Adrenoleukodystrophy","Adrenomyeloneuropathy","Brain Diseases, Metabolic, Inborn","Central Nervous System Diseases","Demyelinating Diseases","White Matter Disorder","Genetic Diseases, X-Linked","Peroxisomal Disorders","Metabolic Diseases","Female Carrier","Adrenoleukodystrophy, women","Heterozygous Carrier","Quality of Life","2025-01-02",{"date":79,"type":40},"2025-01-03",{"date":81,"type":40},"2019-12-01",{"date":83,"type":21},"2027-03-01",{"name":46,"class":47},""]